Geron Go-Ahead Rouses Industry and Researchers
Geron Corp. said today that it hopes to begin within the next two months a clinical trial for an hESC therapy for spinal injuries, triggering a wave of ebullience from scientists, investors and patient advocates.
The company disclosed its plans following the lifting by the FDA of a hold on the effort.
Clive Cookson of the Financial Times of London caught…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.